Lebanese Pharma Algorithm partners with Batterjee Pharma to localize production in Saudi Arabia

SAUDI ARABIA—Algorithm, a leading pharmaceutical manufacturer in the region, has signed a strategic partnership agreement with Batterjee Pharma, a prominent Saudi pharmaceutical company.

This collaboration marks Algorithm as the first Lebanese company to localize its product portfolio within the Kingdom of Saudi Arabia.

The agreement encompasses the manufacturing and supply of several Algorithm products licensed in the European Union and Japan.

The partnership will initially focus on producing medications aimed at treating critical health conditions such as hyperlipidemia, dyslipidemia, and hypertension.

Full technology transfer is planned to be completed by mid-2026, enabling local production to meet the demand efficiently.

This initiative aligns with Saudi Arabia’s Health Sector Transformation Program, a key component of Vision 2030, aimed at strengthening the nation’s healthcare infrastructure and reducing its dependency on imported medicines.

Dr. Mohamed Mazen Batterjee, CEO of Batterjee Pharma, emphasized that the collaboration focuses on ensuring a continuous supply of essential medicines to patients, creating valuable employment opportunities, and increasing local content in line with national development priorities.

He added that this partnership not only improves healthcare access today but also lays the groundwork for a resilient and sustainable pharmaceutical sector across the region.

Batterjee Pharma takes pride in being a dynamic and trustworthy organization that builds meaningful partnerships and brings value through innovation and reliability.

The agreement with Algorithm represents the beginning of multiple collaborative projects between the two companies, highlighting their commitment to advancing the future of healthcare in Saudi Arabia and beyond.

Nabil Ghorayeb, Human Health and Manufacturing Director at Algorithm, described the KSA Localization Project as a bold milestone reflecting Algorithm’s pioneering leadership.

He pointed out that teaming up with Batterjee Pharma enables them to localize the production of highly differentiated therapies that address major unmet medical needs, accelerating access to innovative treatments where they are most needed.

This project supports Saudi Arabia’s Vision 2030, contributing to sustainable economic growth by facilitating knowledge transfer and strengthening healthcare resilience.

More than a localization effort, it serves as a regional blueprint illustrating how purpose-driven innovation can create large-scale impact and help redefine the future of healthcare across the Middle East and North Africa (MENA) region.